BACKGROUND
In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performa...
L. Hauptmann, C. Kronberger, S. Schwarting et al.· Circulation· 0 citations
BACKGROUND
Concomitant severe aortic (AR) and mitral regurgitation (MR) affects up to 25% of patients with aortic valve disease and portends poor prognosis. Evidence on a sequential downstream approach in native AR is limited.
CASE SUMMARY
We report 4 patients with high surgical risk (mean age 82 years, Society of Th...
M. Massussi, Mariafrancesca Forquet, Paolo Scurti et al.· JACC Case Reports· 0 citations
BACKGROUND
The Evolut and the Navitor transcatheter heart valves (THVs) represent the most widely used self-expanding implanted valves. Despite a similar implant concept, they markedly differ in design and hemodynamic performance. In both THVs, conduction disturbances following transcatheter aortic valve replacement (T...
Enrico Poletti, O. Oliva, Ahmad Hassan et al.· Catheterization and cardiova...· 0 citations
BACKGROUND
In patients undergoing tricuspid valve transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR), NYHA functional class guides assessment, but real-world data on its prognostic value and determinants of symptomatic response remain limited.
OBJECTIVES
The objective of the study was to asse...
Charlotte Wolff, P. Sagmeister, K. Fengler et al.· JACC: Advances· 0 citations
Therapeutic developments continue to reshape HF management across the spectrum of left ventricular ejection fraction, and support the transition from a predominantly phenotype-based approach towards a more personalized and biologically informed model of HF care.
Valentino Liguori, Angelica Rizzello, M. Adamo et al.· ESC Heart Failure· 0 citations
An integrated, stepwise management algorithm is proposed that incorporates early risk markers, including natriuretic peptides, to guide the timing of intervention before irreversible myocardial damage occurs and enables more precise patient phenotyping and treatment tailoring.
C. Gaspardone, Paolo Costa, G. Barone et al.· Reviews in cardiovascular me...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.